�����������

Deadline: August 15, 2025

Amount: $294,000 over four years.

Supports the training of the brightest postdoctoral scientists as they embark upon their research careers. This funding enables them to be mentored by established investigators in leading research laboratories across the country.

Research Grant:

Deadline: Aug. 15, 2025

Amount: $75,000 over 1 year

Award: Funds research in the following areas: treatment/therapy, patient care, early diagnosis, detection, cancer biology, basic science, prevention/metabolism and research core facilities.\

Please contact Alex Hood, Associate Director Foundation Relations, at alex.hood@bcm.edu for additional information.

Application Deadline: September 3, 2025

Amount: $150,000 over 2 years

Award: The B+ Foundation funds cutting-edge childhood cancer research. The B+ Foundation funds grants that support basic, translational or clinical research, which may lead towards cures and better treatments for childhood cancers. Applicants may be Assistant, Associate or Professor level investigators.

Please contact: Alex Hood, Associate Director Foundation Relations, at alex.hood@bcm.edu for additional information.

*Limited Institutional Submission Opportunity requiring LOI and Internal Selection

The Cancer Prevention and Research Institute of Texas (CPRIT) has released new RFAs under its Cycle 26.2 Academic Research Program. At this time, the Department of Pediatrics, Section of Hematology and Oncology will begin accepting Letters of Intent from investigators interested in the Multi-Investigator Research Awards (MIRA) mechanism. Only applications that emphasize improving cancer care delivery and survivorship services through research in the childhood and AYA cancer population with be accepted under this RFA.

This is an institutionally limited submission that requires internal coordination and scientific review byPediatrics, Hematology, and Oncology with approval from the DLDCCC for a final nomination. A recommendation for 1 full application will be determined through this process.

MIRA supports highly integrated programs of collaborative and cross-disciplinary research on childhood and/or adolescent and young adult cancer care and survivorship among multiple Texas investigators and institutions. Applications responding to this RFA must emphasize improving cancer care delivery and survivorship services through research in the childhood and AYA cancer population. See RFA and Instructions at the above links for additional information on research objectives.

Key Information:

• Number of Submissions Allowed: Up to 1 application per academic institution
• Funding Amount: Total of $5,000,000 in total costs over five years
• Internal Submission Deadline: FRIDAY, Sep. 05, 2025
• Important Notes:
  • New Proposals only (not renewals)
  • A minimum time commitment of 20% effort is required for the PI and at least 10% effort for each project and core that an MI directs
  • Multi-Principal Investigators (MIs) (Required)
  • Each MIRA must have a minimum of 3 projects (maximum of 5; inclusion of fewer, highly focused projects is strongly recommended) and an Administrative Core. Up to 3 additional technical cores (eg, tissue/biospecimen core, patient registry and data core, sequencing/bioinformatics core, clinical trials core, etc.) are permitted. Projects and cores are subject to different review criteria (see section 11.3 of RFA R-26.2 MIRA). Research projects must not be submitted as cores.
  • A Contact PI or MI may submit only 1 application under this RFA and will not be eligible to participate as a Contact PI or MI on another MIRA application (including subcontracts) in response to this RFA.
  • CPRIT encourages the inclusion of early-stage investigators.
  • Collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds.
• Submissions should include:
  • 5-page LOI: Layperson’s Summary, Specific aims, brief Timeline per Project and Core, Overview of the Program. *References are not needed.
  • Preliminary budget (1 page)
  • Biosketches

If you are interested, please send your current NIH biosketch, Budget, and a five-page LOI as a single PDF file to HemOncPreAwardTeam@texaschildrens.org by FRIDAY, Sep. 05, 2025. These will be reviewed by the Section Internal Review Committee, and then the nomination will be sent to the DLDCCC-appointed panel for approval.

Format Requirement: Please name your pdf file as follows:
NAME OF SPONSOR_PI LAST NAME_LOI
Example: CPRIT_SMITH_LOI

CPRIT Academic Research Program – Cycle 26.2 Opportunities
*Limited Institutional Submission Opportunity requiring LOI and Internal Selection

The Cancer Prevention and Research Institute of Texas (CPRIT) has released new RFAs under its Cycle 26.2 Academic Research Program. At this time, the DLDCCC will begin accepting Letters of Intent from investigators interested in the High-Impact/High-Risk Research Awards (HIHR) mechanism. This is an institutionally limited submission which requires internal coordination and scientific review by the DLDCCC. Recommendations for 5 full applications will be determined through this process.

(login required)

HIHR supports research that explore the feasibility of high-risk projects that, if successful, would contribute to major new insights into the etiology, diagnosis, treatment, or prevention of cancers

• Number of Submissions Allowed: Up to 5 applications from academic institutions
• Funding Amount: Total of $250,000 for a period of up to 2 years.
• Internal Submission Deadline: Mon, Sept. 8, 2025
• Important Notes:
  • New Proposals only (not renewals)
  • PI must commit at least 5% effort
• Submissions should include:
  • 2-page LOI: Layperson’s summary, Specific aims, Research Plans, High-risk rationale, Timeline. Indicate whether this is a new submission or resubmission.
  • Preliminary budget (1page)
  • Biosketches

If you are interested, please upload your current NIH biosketch, Budget, and a two-page LOI as a single PDF file via the BCM Award Hub by Monday, Sept. 8, 2025. This will be reviewed by the DLDCCC-appointed panel.

• Format Requirement: Please name your pdf file as follows:
  NAME OF SPONSOR_PI LAST NAME_LOI
  Example: CPRIT_SMITH_LOI

For inquiries related to submission, please contact DLDCCCgrants@bcm.edu. Thank you.

LOI Deadline: September 11, 2025

Amount: $50,000

Award: Provides research funding to early-career investigators to encourage and promote quality research in global oncology and to develop the next generation of researchers to address global health needs. This is a mentored award and the research project is conducted under the guidance of a scientific mentor.

The Global Oncology Young Investigator Award is intended to support:

Research by investigators in low resource settings on scientific questions specific to those settings. This research has potential to offer “reverse innovation” insights that could influence practice in a wide range of practice settings.

Research by investigators in high resource settings on issues in resource-limited settings.
Collaborative research (high and low resource investigators) on questions of shared concern, such as studying a cancer type that affects a small population in the U.S. but is common in another country.

Please contact: Alex Hood, Associate Director Foundation Relations, at alex.hood@bcm.edu for additional information.

Application Deadline: September 11, 2025

Amount: $50,000

Award: Provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of these grants is to fund physicians during the transition from a fellowship program to a faculty appointment. This is a mentored award and the research project is conducted under the guidance of an experienced mentor in the proposed research area. Applications in the applicable areas of cancer research are accepted from U.S. and international applicants.

Applicants must be a physician (MD, DO, or international equivalent) working in any country and currently in the last two years of their final oncology subspecialty training at an academic medical institution and within 10 years of obtaining their medical degree at the time of grant submission. Examples of subspecialty training include, but are not limited to, a hematology-oncology fellowship, a surgical oncology fellowship, or a radiation oncology residency.

Please contact: Alex Hood, Associate Director Foundation Relations, at alex.hood@bcm.edu for additional information.

LOI deadline: Sept. 30, 2025
Amount: $1,500,000 in funding over a period of three years
Award: Will focus on the science behind HER2 mutations as oncogenic drivers of malignancy and/or the development of novel therapeutic approaches for patients with tumors harboring HER2 mutations.

Please contact Tiffany Gardner Associate Director of Foundation Relations at Tiffany.Gardner@bcm.edu with any questions.

LOI Deadline: Wednesday, October 1, 2025

Amount: $1M to $4M for projects from 1-4 years in duration

This funding call invites proposals that primarily aim to design, validate, and test innovative interventions to prevent cancer recurrence or to detect and intercept early-stage recurrent cancers at the earliest actionable timepoints.

Application Deadline: October 9, 2025

Amount: $200,000 over 3 years

Award: The Career Development Award (CDA) provides research funding to clinical investigators, who have received their initial faculty appointment, as they work to establish an independent clinical cancer research program. This is a mentored award and the research project is conducted under the guidance of a scientific mentor. The research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Applications in all areas of cancer research are accepted from U.S. and international applicants. Must be in the first to fourth year of a full-time primary faculty appointment.

Please contact: Alex Hood, Associate Director Foundation Relations, at alex.hood@bcm.edu for additional information.

LOI Deadline: December 1, 2025
Amount: Up to $1,000,000
Award: To provide funding for clinician-scientists aiming to launch innovative phase I/II or phase II clinical studies using novel immunotherapies. Competitive applications will have a strong focus on yielding mechanistic insights into clinical response and potentials for biomarker discovery and/or validation.

Please contact Andrea Calo Assistant Vice President Foundation Relations at Mary.Calo@bcm.edu with any questions.

Deadline: December 11, 2025

Amount: $250,000 over 2 years

Award: The RARE Grant supports research focused on identifying druggable oncogenic pathways and advancing cancer interception and prevention strategies toward clinical application. Funded projects will demonstrate clear potential to benefit patients and families affected by RUNX1-FPD.

Please contact Alex Hood, Associate Director Foundation Relations at alex.hood@bcm.edu with any questions.

Application Deadline: Ongoing until funds are used.

Budget: $20,000-$40,000, for one year.

Award: The Colon Cancer Coalition seeks to provide funds, to liked-minded partners advancing colon cancer research. Funds must be used on programs that will benefit individuals in and around the event city where the money is raised. Priority will be given to programs working to increase screening for adults over 50 to reach the national goal of 80%, patient screening navigation, or addressing young adult onset colorectal cancer.

Contact: Please contact Lyndsie Whitehead, Assistant Director of Foundation Relations at lyndsie.whitehead@bcm.edu for additional information.

Application Deadline: Funding is available on a rolling basis and new grants are awarded frequently.
Budget: $50,000 ~ $828,027, from 6 months to 36 months (average $224,000 for 2 years). NTAP supports indirect costs at a maximum of 10% of direct costs.  

Award: The Johns Hopkins University School of Medicine - Neurofibromatosis Therapeutic Acceleration Program (NTAP) supports research projects designed to accelerate development of effective treatments for NF1 associated peripheral nerve sheath tumors.  NTAP’s is open to any stage of drug development.  However, proposal must focus on the peripheral nerve tumors of NF1 (Cutaneous, Plexiform and Atypical).

Please contact Lyndsie Whitehead, Assistant Director of Foundation Relations for additional information.